# A Study of Subcutaneous At Home Administration of Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2-positive (HER2+) Early Breast Cancer (eBC)

> **NCT01926886** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 102 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT01926886
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11-19
- **Primary completion:** 2015-09-04
- **Final completion:** 2017-07-19
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2019-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01926886

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01926886, "A Study of Subcutaneous At Home Administration of Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2-positive (HER2+) Early Breast Cancer (eBC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01926886. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*